NCT00030485View on ClinicalTrials.gov

Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2002

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Endometrial Cancer
Interventions
DRUG

erlotinib hydrochloride

Trial Locations (8)

T2N 4N2

Tom Baker Cancer Center - Calgary, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

British Columbia Cancer Agency, Vancouver

L8V 5C2

Margaret and Charles Juravinski Cancer Centre, Hamilton

K7L 5P9

Kingston Regional Cancer Centre, Kingston

N6A 4L6

Cancer Care Ontario-London Regional Cancer Centre, London

M5G 2M9

Princess Margaret Hospital, Toronto

H4L 2M1

Hopital Notre- Dame du CHUM, Montreal

Sponsors
All Listed Sponsors
collaborator

NCIC Clinical Trials Group

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00030485 - Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer | Biotech Hunter | Biotech Hunter